Key Takeaways
- • Delaware Chancery Court approved a $70 million settlement resolving stockholder claims stemming from Covetrus Inc.'s 2022 take-private transaction, delivering what the court determined was a meaningful recovery for investors.
- • The settlement avoids protracted litigation and its associated risks and costs for all parties involved in the dispute.
- • The court's approval validates the adequacy of the settlement amount relative to the claims asserted by stockholders challenging the fairness and process of the original take-private deal.
Summary
The Delaware Chancery Court has approved a $70 million settlement that resolves stockholder litigation challenging the 2022 take-private transaction of Covetrus Inc., an animal health company. The court's decision, rendered on Monday, April 13, 2026, determined that the settlement amount represents a meaningful recovery for investors who challenged the transaction terms and process.
The litigation arose from stockholder claims related to the take-private acquisition announced in 2022. By approving the settlement, the court weighed both the recovery amount available to claimants and the risks inherent in continuing litigation to trial. The settlement structure allows investors to receive compensation without bearing the expense, uncertainty, and timeline risk of prolonged court proceedings.
This approval marks the resolution of a significant shareholder dispute and provides finality to a transaction that had generated investor concerns substantial enough to warrant formal legal action. The $70 million recovery represents a negotiated resolution between the parties, accepted by the court as adequate compensation for the claims asserted. For institutional investors and fund managers holding Covetrus positions during the disputed transaction period, the settlement offers clarity and a defined recovery mechanism.
The litigation arose from stockholder claims related to the take-private acquisition announced in 2022. By approving the settlement, the court weighed both the recovery amount available to claimants and the risks inherent in continuing litigation to trial. The settlement structure allows investors to receive compensation without bearing the expense, uncertainty, and timeline risk of prolonged court proceedings.
This approval marks the resolution of a significant shareholder dispute and provides finality to a transaction that had generated investor concerns substantial enough to warrant formal legal action. The $70 million recovery represents a negotiated resolution between the parties, accepted by the court as adequate compensation for the claims asserted. For institutional investors and fund managers holding Covetrus positions during the disputed transaction period, the settlement offers clarity and a defined recovery mechanism.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.